Comparative proteomics of exosomes secreted by tumoral jurkat t cells and normal human t cell blasts unravels a potential tumorigenic role for valosin-containing protein

Bosque, A. ; Dietz, L. ; Gallego-Lleyda, A. ; Sanclemente, M. ; Iturralde, M. (Universidad de Zaragoza) ; Naval, J. (Universidad de Zaragoza) ; Alava, M.A. (Universidad de Zaragoza) ; Martínez-Lostao, L (Universidad de Zaragoza) ; Thierse, H.J. ; Anel, A. (Universidad de Zaragoza)

Resumen: We have previously characterized that FasL and Apo2L/TRAIL are stored in their bioactive form inside human T cell blasts in intraluminal vesicles present in multivesicular bodies. These vesicles are rapidly released to the supernatant in the form of exosomes upon re-activation of T cells. In this study we have compared for the first time proteomics of exosomes produced by normal human T cell blasts with those produced by tumoral Jurkat cells, with the objective of identify proteins associated with tumoral exosomes that could have a previously unrecognized role in malignancy. We have identified 359 and 418 proteins in exosomes from T cell blasts and Jurkat cells, respectively. Interestingly, only 145 (around a 40%) are common. The major proteins in both cases are actin and tubulin isoforms and the common interaction nodes correspond to these cytoskeleton and related proteins, as well as to ribosomal and mRNA granule proteins. We detected 14 membrane proteins that were especially enriched in exosomes from Jurkat cells as compared with T cell blasts. The most abundant of these proteins was valosin-containing protein (VCP), a membrane ATPase involved in ER homeostasis and ubiquitination. In this work, we also show that leukemic cells are more sensitive to cell death induced by the VCP inhibitor DBeQ than normal T cells. Furthermore, VCP inhibition prevents functional exosome secretion only in Jurkat cells, but not in T cell blasts. These results suggest VCP targeting as a new selective pathway to exploit in cancer treatment to prevent tumoral exosome secretion.

Idioma: Inglés

DOI: 10.18632/oncotarget.8678

Año: 2016

Publicado en: Oncotarget 7 (2016), 29287-29305
ISSN: 1949-2553

Factor impacto JCR: 5.168 (2016)

Categ. JCR: ONCOLOGY rank: 44 / 217 = 0.203 (2016) - Q1 - T1
Categ. JCR: CELL BIOLOGY rank: 48 / 189 = 0.254 (2016) - Q2 - T1

Factor impacto SCIMAGO: 1.994 - Oncology (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MICINN/SAF2010
Financiación: info:eu-repo/grantAgreement/ES/MICINN/SAF2013-48626-C2-1-R

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)